Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

September 11, 2019

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses the heterogeneity of mantle cell lymphoma (MCL).

August 16, 2019

Peter Martin, MD, discusses a phase I trial examining the ibrutinib plus palbociclib combination in ibrutinib-resistant patients with mantle cell lymphoma.

August 15, 2019

Leticia Varella, MD, discusses the progression of available treatments in hormone receptor-positive, HER2-negative metastatic breast cancer.

August 09, 2019

Tessa Cigler, MD, MPH, discusses the agents that are improving survival for women with early-stage and metastatic HER2-positive breast cancers.

August 07, 2019

Alan B. Astrow, MD, discusses the latest efforts to personalize patient care in early-stage, HR-positive, HER2-negative breast cancer.

August 06, 2019

Eleni Andreopoulou, MD, discusses the impact of the IMpassion130 trial on TNBC treatment and the use of immunotherapy in this patient population.

August 06, 2019

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses standard of care for younger patients with mantle cell lymphoma.

August 05, 2019

Eleni Andreopoulou, MD, associate professor of clinical medicine, Weill Cornell Medical College, associate attending physician, NewYork-Presbyterian Hospital, discusses shifts in the treatment paradigm of metastatic triple-negative breast cancer (TNBC) and the impact immunotherapy has had in the field.

August 02, 2019

Lisa Newman, MD, MPH, FACS, FASCO, highlights the history and ongoing research of the genotype causing predisposition to TNBC in African-American women.

July 17, 2019

Scott T. Tagawa, MD, discusses the impact of the BRCA2 mutation in patients with prostate cancer who are receiving prostate-specific membrane antigen–targeted radionuclide therapy.

April 25, 2019

Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, discusses health disparities among women with breast cancer.

April 09, 2019

The R2 regimen of lenalidomide plus rituximab significantly reduced the risk of disease progression or death compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to results from the pivotal phase III AUGMENT trial.

March 28, 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses darolutamide in castration-resistant prostate cancer.

March 05, 2019

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflects on progress made in prostate cancer.

February 09, 2019

Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.

January 31, 2019

Allyson J. Ocean, MD, discusses the potential impact of SM-88 in the treatment of patients with advanced pancreatic cancer and highlights a platform that patients can use to stay updated on the latest research in the field.

December 11, 2018

Scott T. Tagawa, MD, MS, discusses the clinical significance of recent clinical trial data in patients with nonmetastatic prostate cancer.

November 21, 2018

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

November 08, 2018

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses radiotherapy in the treatment of patients with prostate cancer.

October 02, 2018

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the recent progress with HER2-targeted therapy in the treatment of breast cancer.